Loading
Cancer Related Molecular Mechanisms Research · Journal article
Carcinogenesis · August 28, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of non-coding RNA biology in cancer, covering mechanistic roles, biomarker potential, and emerging therapeutic approaches. It synthesizes existing literature on how ncRNAs contribute to cancer initiation, progression, and treatment resistance, but does not present new clinical trial evidence or definitive clinical efficacy data.
Narrative review.
Four major ncRNA classes (miRNAs, lncRNAs, circRNAs, piRNAs) function as either oncogenes or tumour suppressors depending on cancer type. ncRNA stability, cell-type-specific expression, and presence in biofluids make them suitable candidates for biomarker discovery and liquid biopsy applications. Therapeutic strategies include antisense oligonucleotides, siRNAs, synthetic miRNA mimics, RNA aptamers, and aptamer-siRNA conjugates.
No clinical trial efficacy data, safety data, or outcome measures reported.
Clinicians and researchers should recognize ncRNAs as emerging biomarker and therapeutic targets, but recognize that CRISPR and most ncRNA-directed therapies remain investigational with significant translation barriers. Current clinical utility is primarily in biomarker and liquid biopsy contexts.
A narrative review synthesizing mechanistic and exploratory evidence on ncRNA roles in cancer; raises questions about therapeutic potential rather than answering them with clinical trial data.
As stated by the source record.
Clinicians and researchers should recognize ncRNAs as emerging biomarker and therapeutic targets, but recognize that CRISPR and most ncRNA-directed therapies remain investigational with significant translation barriers. Current clinical utility is primarily in biomarker and liquid biopsy contexts.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Non-coding RNAs (ncRNAs) regulate gene expression through transcriptional, post-transcriptional, and epigenetic mechanisms, shaping hallmarks of cancer, including metastasis, therapy resistance, and relapse. Carcinogenesis arises when aberrant ncRNA networks initiate malignant transformation and sustain oncogenic changes through epigenetic modifications, shifts in cell identity, failures in genome protection, metabolic changes, and alterations in the tumour microenvironment. Environmental exposures, combined with chronic inflammation, reorganise these networks early on, leading to the formation of premalignant fields and persistent epigenetic changes. The four major ncRNA classes, microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and PIWI-interacting RNAs (piRNAs) function as either oncogenes or tumour suppressors depending on the specific cancer type. Their stability, cell-type-specific expression, and presence in biofluids make them suitable candidates for biomarker discovery and liquid biopsy applications. Therapeutic strategies now include antisense oligonucleotides, small interfering RNAs, synthetic miRNA mimics, RNA aptamers, and aptamer-siRNA conjugates, which can either inhibit oncogenic ncRNAs or restore tumour-suppressive regulatory networks. CRISPR-based ncRNA modulation, including Cas9-mediated locus editing, CRISPR interference/activation, and Cas13-mediated transcript targeting, remains largely investigational because delivery, off-target activity, and an incomplete understanding of ncRNA context dependence continue to limit translation. High-throughput sequencing, single-cell transcriptomics, and computational modelling have accelerated the identification of cancer-related ncRNAs and elucidated their biological functions. This review examines how different types of ncRNAs contribute to cancer initiation, progression, and treatment resistance, and assesses their potential as diagnostic markers, prognostic factors, and therapeutic targets.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.